HOWARD JAFFE, M.D.
Ambulatory Health at Eugene St, Mill Valley, CA
License number
California G51582
Category
Ambulatory Health
Type
Corporate Health
Address
Address
22 Eugene St, Mill Valley, CA 94941
Phone
(650) 522-5702
Professional information
Dr. Howard S Jaffe, Mill Valley CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
22 Eugene St, Mill Valley 94941
(650) 522-5702 (Phone)
300 Lakeside Dr, San Mateo 94404
(650) 522-5702 (Phone)
300 Lakeside Dr, San Mateo 94404
Certifications:
Internal Medicine, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Yale University
University Of California-San Francisco
Yale University
University Of California-San Francisco
Method Of Treatment And Pharmaceutical Compositions
US Patent:
2010016, Jun 24, 2010
Filed:
Jun 19, 2009
Appl. No.:
12/487890
Inventors:
Howard S. Jaffe - Mill Valley CA, US
Hans C. Reiser - San Francisco CA, US
Clifford Dean Wright - Sammamish WA, US
Hans C. Reiser - San Francisco CA, US
Clifford Dean Wright - Sammamish WA, US
Assignee:
Gilead Sciences, Inc. - Foster City CA
International Classification:
A61K 31/4725, A61P 11/00
US Classification:
514307
Abstract:
The present invention relates to methods, uses, and compositions comprising the caspase inhibitor (R)-N-((2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxo-tetrahydrofuran-3-yl)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
Method Of Treatment And Pharmaceutical Compositions
US Patent:
2010000, Jan 14, 2010
Filed:
Jun 19, 2009
Appl. No.:
12/487865
Inventors:
Howard S. Jaffe - Mill Valley CA, US
Hans C. Reiser - San Francisco CA, US
Franck Rousseau - Durham NC, US
Geoffrey Yuen - Cary NC, US
Hans C. Reiser - San Francisco CA, US
Franck Rousseau - Durham NC, US
Geoffrey Yuen - Cary NC, US
Assignee:
Gilead Sciences, Inc. - Foster City CA
International Classification:
A61K 9/12, A61K 31/4725, A61K 31/155, A61K 31/426
US Classification:
424 45, 514307, 514635, 514369
Abstract:
The present invention relates to methods, uses, and compositions comprising the caspase inhibitor (R)-N-((2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxo-tetrahydrofuran-3-yl)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.